• Home
  • About Us
  • Resources
  • Team
    • Leadership Team
    • Advisory Board
  • News
    • Press Releases
    • Bridge In The News
    • Other News
  • Contact
Bridge Therapeutics
Bridge Therapeutics

Other News

Other news from bridge therapeutics
7th December 2017

Let’s fix the cause, rather than the problem, of opioid addiction

A recent article published on the website The Hill discusses the problem of prescribing addictive schedule III drugs for pain relief rather than the equally effective and non-addictive schedule II drugs.  

READ MORE
«123
Categories
  • Press Releases
  • Bridge In The News
  • Other News

For more information about Bridge Therapeutics please contact us today using the form below.

Investors Click HerePhysicians Click Here

CONTACT US

If you would like to learn more about Bridge Therapeutics please use the contact form below.




All fields marked with * are required.

217 Country Club Park
Ste. 325
Birmingham, AL, 35213

T: 877-223-6949

 

Bridge Therapeutics

Bridge Therapeutics, Inc. is a development-stage pharmaceutical company pursuing FDA approval of BT‑219, a superior form of buprenorphine-naloxone for opioid use disorder (OUD), and approval of BT-205, a patented drug combination for the treatment of chronic pain in opioid-experienced patients (U.S. Patent #8410092).

© Copyright Bridge Therapeutics 2023. Bridge Therapeutics is a registered trademark of Bridge Therapeutics Inc.
All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.